Trilogy Transcatheter Heart Valve System
JenaValve Technology, Inc. · Decision date Oct 13, 2026
What did the FDA decide?
The FDA record for P250024/S005, dated 2026-10-13, is a 30-Day Notice under the Trilogy Transcatheter Heart Valve System PMA, filed by JenaValve Technology, Inc. The supplement reason is Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the stated change is "an additional abattoir for sourcing pericardium tissue." The device category is a percutaneously delivered aortic valve prosthesis (product code NPT).
Because the record names P250024, this submission modifies the existing PMA rather than granting approval of the whole system; the decision is logged as OK30, and the notice concerns a supplier arrangement for pericardium tissue sourcing. The supplied fields do not identify the abattoir, its location, tissue acceptance criteria, or any verification data tied to the added source. The stated purpose of the notice is not evidence of safety or clinical effectiveness.
FDA approval order statement
an additional abattoir for sourcing pericardium tissue
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 13, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250024/S005
- Regulatory pathway
- PMA supplement
- Applicant
- JenaValve Technology, Inc.
- Product code
- NPT
- Decision code
- OK30
- Decision date
- Oct 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Aortic valve, prosthesis, percutaneously delivered.
- Applicant
- JenaValve Technology, Inc.
- Product code
- NPT
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250024. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250024 · Original PMA
Trilogy Transcatheter Heart Valve System
P250024/S005 received
Application receipt date recorded by FDA.
P250024/S006 · Related supplement
Trilogy Transcatheter Heart Valve System
P250024/S005 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P250024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| JenaValve Technology, Inc. | PMA approval | Mar 17, 2026 | FDA | |
Trilogy Transcatheter Heart Valve SystemP250024/S006 | JenaValve Technology, Inc. | PMA supplement | Oct 7, 2026 | FDA |
Explore the linked device profile
Other records with product code NPT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Nov 7, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 29, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Sep 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
JenaValve Technology, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4 Cromwell, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P250024/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
